Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Preclinical Characterization of CLSP-1025, a First-in-Class, Mutation-Specific T-Cell Engager Targeting a Neoantigen Derived from a Common p53 Mutation. Local targets link to admitted publications; unresolved targets remain external evidence.
An immune-active tumor microenvironment favors clinical response to ipilimumab
10.1007/s00262-011-1172-6 · 2012 · External reference
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: current knowledge and practical recommendations
10.1016/j.ctrv.2024.102751 · 2024 · External reference
PD-1 blockade induces responses by inhibiting adaptive immune resistance
10.1038/nature13954 · 2014 · External reference
Challenges and new technologies in adoptive cell therapy
10.1186/s13045-023-01492-8 · 2023 · External reference
Bispecific antibodies in hematologic and solid tumors: current landscape and therapeutic advances
10.1200/edbk-25-473148 · 2025 · External reference
T cell engagers: expanding horizons in oncology and beyond
10.1038/s41416-025-03125-y · 2025 · External reference
Five-year survival with tebentafusp in metastatic uveal melanoma
10.1016/j.annonc.2026.05.695 · External reference
Tarlatamab in small-cell lung cancer after platinum-based chemotherapy
10.1056/nejmoa2502099 · 2025 · External reference
Neoantigens: promising targets for cancer therapy
10.1038/s41392-022-01270-x · 2023 · External reference
Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer
10.1186/s12885-022-10039-y · 2022 · External reference
Mutant p53 as a target for cancer treatment
10.1016/j.ejca.2017.06.023 · 2017 · External reference
Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
10.1172/jci123791 · 2019 · External reference
Immunologic recognition of a shared p53 mutated neoantigen in a patient with metastatic colorectal cancer
10.1158/2326-6066.cir-18-0686 · 2019 · External reference
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
10.1038/nm.4333 · 2017 · External reference
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
10.1038/nrclinonc.2017.151 · 2018 · External reference
Targeting a neoantigen derived from a common TP53 mutation
10.1126/science.abc8697 · 2021 · External reference
Systematic discovery of neoepitope-HLA pairs for neoantigens shared among patients and tumor types
10.1038/s41587-023-01945-y · 2024 · External reference
AACR Project GENIE: powering precision medicine through an international consortium
10.1158/2159-8290.cd-17-0151 · 2017 · External reference
The function of the mutant p53-R175H in cancer
10.3390/cancers13164088 · 2021 · External reference
The most frequent HLA alleles around the world: a fundamental synopsis
10.1016/j.beha.2024.101559 · 2024 · External reference
393 A non-virally engineered T cell therapy targeting the hotspot mutation R175H in TP53 with signals 1, 2, and 3 (TCR, co-stimulation, and cytokine) drives a coordinated antitumor CD4/8 T cell response
10.1136/jitc-2024-sitc2024.0393 · 2024 · External reference
Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors
10.1158/2326-6066.cir-22-0040 · 2022 · External reference
Non-clinical evaluation of NT-175, an autologous T cell product engineered to express an HLA-A*02:01-restricted TCR targeting TP53 R175H and resistant to TGF-b inhibition
10.1200/jco.2024.42.16_suppl.2560 · 2024 · External reference
A study of NT-175 in adult subjects with unresectable, advanced, and/or metastatic solid tumors that are positive for HLA-A*02:01 and the TP53 R175H mutation
2025 · External reference
Initial phase 1 study results of NT-175 engineered T-cell therapy in TP53 R175H–mutated unresectable advanced solid tumors
10.1200/jco.2026.44.16_suppl.2506 · 2026 · External reference
1061 CLSP-1025, a novel bispecific T-cell engager targeting a p53 R175H mutant peptide presented by HLA-A*02:01
10.1136/jitc-2024-sitc2024.1061 · 2024 · External reference
Abstract 1126: CLSP-1025, a first-in-class precision T cell engager for the treatment of p53 mutant cancers
10.1158/1538-7445.am2025-1126 · 2025 · External reference
SOP30101: recipes for complete media for patient-derived in vitro and organoid cultures
2024 · External reference
SOP40103: passaging and sub-culture of patient-derived organoid (PDOrg) cultures
2020 · External reference
Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate
10.1080/2162402x.2018.1532759 · 2019 · External reference
Logomaker: beautiful sequence logos in Python
10.1093/bioinformatics/btz921 · 2020 · External reference
ScanProsite: detection of PROSITE signature matches and ProRule-associated functional and structural residues in proteins
10.1093/nar/gkl124 · 2006 · External reference
The immune landscape of cancer
10.1016/j.immuni.2018.03.023 · 2018 · External reference
Common, intermediate and well-documented HLA alleles in world populations: CIWD version 3.0.0
10.1111/tan.13811 · 2020 · External reference
The IPD-IMGT/HLA database
10.1093/nar/gkac1011 · 2023 · External reference
25 years of the IPD-IMGT/HLA database
10.1111/tan.15549 · 2024 · External reference
Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega
10.1038/msb.2011.75 · 2011 · External reference
Interactive Tree of Life (iTOL) v6: recent updates to the phylogenetic tree display and annotation tool
10.1093/nar/gkae268 · 2024 · External reference
Unresolved reference
2011 · External reference
1197 Optimizing a T cell-engaging bispecific antibody targeting the highly recurrent p53 R175H neoantigen via affinity maturation
10.1136/jitc-2022-sitc2022.1197 · 2022 · External reference
Bispecific antibodies and CAR T cells targeting a TP53 mutation–associated neoantigen show discordant affinity requirements
10.1172/jci192885 · 2026 · External reference
Format and geometries matter: structure-based design defines the functionality of bispecific antibodies
10.1016/j.csbj.2020.05.006 · 2020 · External reference
T-cell activation-induced marker assays in health and disease
10.1111/imcb.12636 · 2023 · External reference
Platelets present antigen in the context of MHC class I
10.4049/jimmunol.1200580 · 2012 · External reference
Interferon gamma, MHC class I regulation and immunotherapy
10.33696/signaling.3.065 · 2022 · External reference
Interferon γ and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity
10.1101/cshperspect.a028480 · 2019 · External reference
Allelefrequencies.net
2025 · External reference
Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4
10.4049/jimmunol.164.4.1925 · 2000 · External reference
Effect of a single amino acid mutation on the activating and immunosuppressive properties of a “humanized” OKT3 monoclonal antibody
10.4049/jimmunol.148.11.3461 · 1992 · External reference
Improving adoptive T cell therapy: the particular role of T cell costimulation, cytokines, and post-transfer vaccination
10.3389/fimmu.2016.00345 · 2016 · External reference
Human leukocyte antigen class I antigen-processing machinery upregulation by anticancer therapies in the era of checkpoint inhibitors: a review
10.1001/jamaoncol.2021.5970 · 2022 · External reference
1600O Efficacy and safety of IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal melanoma from a phase I trial
10.1016/j.annonc.2025.08.2228 · 2025 · External reference
Bispecific antibodies in hematological malignancies: a scoping review
10.3390/cancers15184550 · 2023 · External reference
Overall survival benefit with tebentafusp in metastatic uveal melanoma
10.1056/nejmoa2103485 · 2021 · External reference
Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp
10.1016/j.ejca.2023.112986 · 2023 · External reference
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer
10.1002/cncr.35738 · 2025 · External reference
Transcriptome analyses of taste organoids reveal multiple pathways involved in taste cell generation
10.1038/s41598-017-04099-5 · 2017 · External reference
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors
10.1038/s41698-022-00334-z · 2022 · External reference
Oncogenic activation of PI K3 CA in cancers: emerging targeted therapies in precision oncology
10.1016/j.gendis.2024.101430 · 2025 · External reference
A study of CLSP-1025 in adult patients with solid tumors that harbor the p53 R175H mutation (GUARDIAN-101)
2025 · External reference
